Virtual Multidisciplinary Tumor Boards: A Narrative Review Focused on Lung Cancer.

Lung cancer Multidisciplinary tumor boards Oncology networks Virtualization

Journal

Pulmonary therapy
ISSN: 2364-1746
Titre abrégé: Pulm Ther
Pays: United States
ID NLM: 101687144

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 08 03 2021
accepted: 20 05 2021
pubmed: 6 6 2021
medline: 6 6 2021
entrez: 5 6 2021
Statut: ppublish

Résumé

To date, the virtual multidisciplinary tumor boards (vMTBs) are increasingly used to achieve high-quality treatment recommendations across health-care regions, which expands and develops the local MTB team to a regional or national expert network. This review describes the process of lung cancer-specific MTBs and the transition process from face-to-face tumor boards to virtual ones. The review also focuses on the project organization's description, advantages, and disadvantages. Semi-structured interviews identified five major themes for MTBs: current practice, attitudes, enablers, barriers, and benefits for the MTB. MTB teams exhibited positive responses to modeled data feedback. Virtualization reduces time spent for travel, allowing easier and timely patient discussions. This process requires a secure web platform to assure the respect of patients' privacy and presents the same unanswered problems. The implementation of vMTB also permits the implementation of networks especially in areas with geographical barriers facilitating interaction between large referral cancer centers and tertiary or community hospitals as well as easier access to clinical trial opportunities. Studies aimed to improve preparations, structure, and conduct of MTBs, research methods to monitor their performance, teamwork, and outcomes are also outlined in this article. Analysis of literature shows that MTB participants discuss 5-8 cases per meeting and that the use of a vMTB for lung cancer and in particular stage III NSCLC and complex stage IV cases is widely accepted by most health professionals. Despite still-existing gaps, overall vMTB represents a unique opportunity to optimize patient management in a patient-centered approach.

Identifiants

pubmed: 34089169
doi: 10.1007/s41030-021-00163-8
pii: 10.1007/s41030-021-00163-8
pmc: PMC8177259
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

295-308

Informations de copyright

© 2021. The Author(s).

Références

JMIR Res Protoc. 2021 Sep 10;10(9):e26220
pubmed: 34387553
BMC Cancer. 2020 Apr 28;20(1):355
pubmed: 32345242
Transl Lung Cancer Res. 2020 Aug;9(4):1667-1679
pubmed: 32953540
BMC Health Serv Res. 2018 Apr 5;18(1):249
pubmed: 29622020
Oncologist. 2021 Feb;26(2):e306-e315
pubmed: 33145902
PLoS One. 2020 Oct 8;15(10):e0236503
pubmed: 33031375
J Multidiscip Healthc. 2020 Feb 14;13:179-186
pubmed: 32103978
Transl Lung Cancer Res. 2020 Jun;9(3):507-514
pubmed: 32676314
Cancer. 2001 Apr 1;91(7):1231-7
pubmed: 11283921
Cancer Treat Res Commun. 2020;25:100231
pubmed: 33157512
Head Neck. 2020 Jun;42(6):1310-1316
pubmed: 32329958
JMIR Med Inform. 2018 Apr 18;6(2):e24
pubmed: 29669706
Br J Cancer. 2006 Oct 23;95(8):979-85
pubmed: 17047646
BMC Cancer. 2017 Nov 17;17(1):772
pubmed: 29149872
JTO Clin Res Rep. 2020 Nov 1;1(4):100073
pubmed: 33225316
J Oncol Pract. 2013 May;9(3):e77-80
pubmed: 23942505
Asia Pac J Clin Oncol. 2020 Feb;16(1):45-55
pubmed: 31721458
Chest. 2020 Dec;158(6):2675-2687
pubmed: 32738254
BMC Med. 2007 Jun 13;5:15
pubmed: 17567904
J Thorac Oncol. 2007 Jan;2(1):69-72
pubmed: 17410013
NPJ Digit Med. 2020 Feb 6;3:17
pubmed: 32047862
J Healthc Manag. 2014 May-Jun;59(3):177-93
pubmed: 24988672
Cancer. 2011 Nov 15;117(22):5112-20
pubmed: 21523766
Biology (Basel). 2020 Dec 25;10(1):
pubmed: 33375573
Lancet Oncol. 2020 Dec;21(12):e539
pubmed: 33271096
Lung Cancer. 2018 Oct;124:199-204
pubmed: 30268461
Ann Glob Health. 2019 Jan 22;85(1):
pubmed: 30741509
BMJ Open. 2017 Dec 28;7(12):e018629
pubmed: 29288182
BMJ. 2012 Apr 26;344:e2718
pubmed: 22539013
Diagnostics (Basel). 2017 Oct 17;7(4):
pubmed: 29039744
Transl Lung Cancer Res. 2020 Aug;9(4):1629-1638
pubmed: 32953537
J Multidiscip Healthc. 2016 Mar 30;9:137-44
pubmed: 27099511
Eur J Cardiothorac Surg. 2018 Jun 1;53(6):1199-1204
pubmed: 29293943
BMC Health Serv Res. 2020 Jan 31;20(1):73
pubmed: 32005232
J Oncol Pract. 2015 May;11(3):e267-78
pubmed: 25922221
JCO Clin Cancer Inform. 2020 Jul;4:602-613
pubmed: 32644817
World J Urol. 2018 Jul;36(7):1031-1038
pubmed: 29502300
PLoS One. 2019 Nov 13;14(11):e0224027
pubmed: 31721773
J Multidiscip Healthc. 2020 Nov 27;13:1729-1739
pubmed: 33273821
Transl Lung Cancer Res. 2020 Aug;9(4):1422-1432
pubmed: 32953514
J Thorac Dis. 2019 Mar;11(Suppl 4):S562-S565
pubmed: 31032074
PLoS One. 2015 May 12;10(5):e0126547
pubmed: 25966317
Laryngoscope Investig Otolaryngol. 2020 Jan 19;5(1):46-54
pubmed: 32128430
Transl Lung Cancer Res. 2020 Aug;9(4):1690-1698
pubmed: 32953542
Lung Cancer. 2008 Apr;60(1):14-21
pubmed: 18304687
Am Soc Clin Oncol Educ Book. 2018 May 23;38:540-545
pubmed: 30231354
N Engl J Med. 2004 Jan 22;350(4):379-92
pubmed: 14736930

Auteurs

Vittorio Gebbia (V)

Medical Oncology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, La Maddalena Clinic for Cancer, University of Palermo, Via San Lorenzo Colli n. 312D, 90100, Palermo, Italy. vittorio.gebbia@gmail.com.
GSTU Foundation, Palermo, Italy. vittorio.gebbia@gmail.com.

Aurelia Guarini (A)

Medical Oncology Unit, Fondazione Ospedale Giglio, Cefalù, Palermo, Italy.

Dario Piazza (D)

GSTU Foundation, Palermo, Italy.

Alessandro Bertani (A)

Division of Thoracic Surgery and Lung Transplantation, Department for the Treatment and Study of Cardiothoracic Diseases and Cardiothoracic Transplantation, IRCCS Ismett, UPMC, Palermo, Italy.

Massimiliano Spada (M)

Medical Oncology Unit, Fondazione Ospedale Giglio, Cefalù, Palermo, Italy.

Francesco Verderame (F)

Medical Oncology Unit, Ospedale Cervello Villa Sofia, Palermo, Italy.

Concetta Sergi (C)

Thoracic Surgery Unit, ARNAS, Ospedale Garibaldi, Nesima, Catania, Italy.

Enrico Potenza (E)

Thoracic Surgery Unit, ARNAS, Ospedale Garibaldi, Nesima, Catania, Italy.

Ivan Fazio (I)

Radiation Therapy Unit, Clinica Macchiarella, Palermo, Italy.

Livio Blasi (L)

Medical Oncology Unit, Arnas Civico, Palermo, Italy.

Alba La Sala (A)

Bronchial Endoscopy Unit, Arnas Civico, Palermo, Italy.

Gianluca Mortillaro (G)

Radiation Therapy Unit, Arnas Civico, Palermo, Italy.

Elena Roz (E)

Pathology Unit, La Maddalena Clinic for Cancer, Palermo, Italy.

Roberto Marchese (R)

Thoracic Surgery Unit, La Maddalena Clinic for Cancer, Palermo, Italy.

Maurizio Chiarenza (M)

Medical Oncology Unit, Istituto Clinico Humanitas, Catania, Italy.

Hector Soto-Parra (H)

Medical Oncology Unit, Policlinico, Catania, Italy.

Maria Rosaria Valerio (MR)

Medical Oncology Unit, Policlinico, Palermo, Italy.

Giuseppe Agneta (G)

Thoracic Surgery Unit, Ospedale Cervello Villa Sofia, Palermo, Italy.

Carmela Amato (C)

Patients Advocacy "Serena a Palermo", Palermo, Italy.

Helga Lipari (H)

Medical Oncology Unit, Ospedale Cannizzaro, Catania, Italy.

Sergio Baldari (S)

Nuclear Medicine Unit, Department of Biomedical and Dental Sciences and Morpho-Functional Imaging, University Hospital G. Martino, Messina, Italy.

Francesco Ferraù (F)

Medical Oncology Unit, Ospedale San Vincenzo, Taormina, Messina, Italy.

Alfio Di Grazia (A)

Radiation Oncology Unit, Istituto Clinico Humanitas, Catania, Italy.

Gianfranco Mancuso (G)

Medical Oncology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, La Maddalena Clinic for Cancer, University of Palermo, Via San Lorenzo Colli n. 312D, 90100, Palermo, Italy.

Sergio Rizzo (S)

Medical Oncology Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, La Maddalena Clinic for Cancer, University of Palermo, Via San Lorenzo Colli n. 312D, 90100, Palermo, Italy.

Alberto Firenze (A)

Risk Management Unit, Policlinico, University of Palermo, Palermo, Italy.

Classifications MeSH